Code
MOG-RXTX-01BV
Test
Active-Compendium
81401
Clinical
Oncology,Pathology
<p><b>Bone Marrow Aspirate:</b> 2 mL in EDTA tube.<br>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>Note:</b> Test is RNA-based. Please select Extract & Hold - RNA if specimen hold service is desired.</p>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>Note:</b> Test is RNA-based. Please select Extract & Hold - RNA if specimen hold service is desired.</p>
Flag Active
True
Orderable Test Description
This test uses real-time RT-PCR for quantitative detection of the t(8;21) RUNX1-RUNX1T1 fusion transcript (formerly called AML1-ETO). Analytical sensitivity is 1 tumor cell in 100,000 normal cells. Positive results are reported as a ratio between quantities of (8;21) transcript and a normal control gene.
Orderable Turn Around Time
7 Days
Keywords
Orderable Biomarkers
NY Approved
False
Orderable Biomarkers JSON
{"FISH": {"Translocation(s)": ["RUNX1-RUNX1T1"]}}
Keywords string
RUNX1, RUNX1T1, AML1, ETO, Translocation, RUNX1 RUNX1T1, AML1 ETO RUNX1-RUNX1T1 (AML1-ETO) Translocation, t(8;21)
Title URL
runx1-runx1t1-aml1-eto-translocation-t8-21
Clinical Significance
The (8;21) translocation occurs in approximately 5% of AML. These cases are usually considered core-binding factor AML (CBF-AML). The translocation is usually associated with a high rate of complete remission and longer overall survival in AML subtype M2. This assay is recommended for diagnostic confirmation of and for monitoring minimal residual disease (MRD) and predicting relapse. For monitoring MRD, we recommend monitoring trend rather than the absolute value of a single measurement.
Storage and transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. Please select Extract & Hold - RNA if specimen hold service is desired.